- Home
- AXS vs AXSM Comparison
AXS vs AXSM Comparison
Compare AXS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXS | AXSM |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | Bermuda | United States |
| Employees | 1876 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | AXS | AXSM |
|---|---|---|
| Price | $100.08 | $160.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | $121.86 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 613.3K | 468.7K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.36 | $58.34 |
| Revenue Next Year | $6.20 | $54.30 |
| P/E Ratio | $8.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.81 | $86.99 |
| 52 Week High | $110.34 | $191.50 |
Technical Indicators
Market Signals| Indicator | AXS | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 34.37 |
| Support Level | $99.15 | $148.14 |
| Resistance Level | $103.65 | $191.13 |
| Average True Range (ATR) | 2.37 | 5.42 |
| MACD | -0.46 | -1.09 |
| Stochastic Oscillator | 6.61 | 4.78 |
Price Performance
Historical ComparisonAbout AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.